Hemodynamic effects of digoxin in acute myocardial infarction in man: a randomized controlled trial. 1985

N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi

Hemodynamic effects of digoxin in acute myocardial infarction (AMI) have been acknowledged to depend on the basal cardiocirculatory state. In the present study, the effects of digoxin in patients with AMI were evaluated in four hemodynamic subsets, based on the relationship between mean pulmonary capillary wedge pressure (PCWP, in mm Hg) and left ventricular stroke work index (LVSWI, in g-m/m2): subset 1: normal (less than or equal to 15 mm Hg) PCWP and normal (greater than or equal to 35 g-m/m2) LVSWI; subset 2: elevated (greater than 15 mm Hg) PCWP and normal LVSWI; subset 3: reduced (less than 35 g-m/m2) LVSWI and normal PCWP; and subset 4: elevated PCWP and LVSWI moderately reduced to a range between 16 and 34 g-m/m2. Forty patients were admitted to the study and were randomly assigned to one of two groups in each subset: control group (19 patients) and treated group (21 patients). Five patients were randomized into each of the subsets 2, 3, and 4 in both the control and treated groups, while in subset 1 there were four control and six digoxin-treated patients. Control patients were administered a placebo saline solution and digoxin-treated patients received 0.50 mg of the drug intravenously in 20 minutes. The effects of the placebo and of the drug were evaluated at 30, 60, and 90 minutes from the end of the infusion. Hemodynamic data did not vary in the control group, and digoxin did not exert any relevant effect in subsets 1 and 2. After drug infusion, cardiac index (Cl, in L/min/m2) significantly increased in subset 3 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011669 Pulmonary Wedge Pressure The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES. Pulmonary Artery Wedge Pressure,Pulmonary Capillary Wedge Pressure,Pulmonary Venous Wedge Pressure,Wedge Pressure,Pressure, Pulmonary Wedge,Pressures, Pulmonary Wedge,Pulmonary Wedge Pressures,Wedge Pressure, Pulmonary,Wedge Pressures, Pulmonary,Pressure, Wedge,Pressures, Wedge,Wedge Pressures
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
May 1967, Progress in cardiovascular diseases,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
November 1985, The American journal of cardiology,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
June 1971, The American journal of cardiology,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
January 1973, The Medical clinics of North America,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
February 1984, The American journal of cardiology,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
June 1986, American heart journal,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
November 1987, Critical care medicine,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
March 1985, Japanese heart journal,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
July 1993, Journal of the American College of Cardiology,
N Marchionni, and R Pini, and A Vannucci, and A Conti, and W De Alfieri, and M Calamandrei, and M Di Bari, and L Ferrucci, and G Moschi, and A Lombardi
February 1985, The American journal of cardiology,
Copied contents to your clipboard!